Platinum, Palladium...
Health Care: Drugs
Synergy Pharmaceuticals Inc. (SGYP: NASDAQ)
$4.81 -0.15 | -3.02%
06/19/13 - 04:00 PM ET
Company Cash Flow
| Dec 2012 | Dec 2011 | Dec 2010 | Dec 2009 | |
| Cash Flow From Operating Activities | ||||
|---|---|---|---|---|
| Net Income (Loss) | -39.44M | -14.47M | -15.22M | -8.13M |
| Operating Gains/Losses | 2.00K | 0.00 | 0.00 | 0.00 |
| Extraordinary Gains / Losses | 0.00 | 0.00 | 0.00 | 0.00 |
| (Increase) Decrease In Receivables | 0.00 | 0.00 | 0.00 | 0.00 |
| (Increase) Decrease in Inventories | 0.00 | 0.00 | 0.00 | 0.00 |
| (Increase) Decrease In Other Current Assets | 0.00 | 0.00 | 0.00 | 0.00 |
| (Decrease) Increase In Payables | 4.44M | -2.27M | 3.29M | -351.50K |
| (Decrease) Increase In Other Current Liabilities | 0.00 | 0.00 | 0.00 | 0.00 |
| (Increase) Decrease In Other Working Capital | -5.00K | 0.00 | 0.00 | -9.62K |
| Other Non-Cash Items | 4.36M | -4.43M | 415.37K | 1.05M |
| Net Cash From Continuing Operations | -31.12M | -21.23M | -11.45M | -8.49M |
| Net Cash From Discontinued Operations | 0.00 | 0.00 | 0.00 | 0.00 |
| Cash Provided By Investing Activities | ||||
| Net Cash From Total Operating Activities | -31.12M | -21.23M | -11.45M | -8.49M |
| Sale of Property, Plant & Equipment | 0.00 | 0.00 | 0.00 | 0.00 |
| Cash Used for Investing Activities | ||||
| Sale of Short-Term Investments | 0.00 | 0.00 | 0.00 | 0.00 |
| Purchases of Property, Plant & Equipment | -28.00K | 0.00 | 0.00 | 0.00 |
| Acquisitions | 0.00 | 0.00 | 0.00 | 0.00 |
| Purchases of Short-Term Investments | 0.00 | 0.00 | 0.00 | 0.00 |
| Other Cash from Investing Activities | -1.76M | 132.63K | -701.54K | -282.22K |
| Cash Provided by Financing Activities | ||||
| Net Cash From Investing Activities | -21.79M | 132.63K | -701.54K | -282.22K |
| Issuance of Debt | 0.00 | 0.00 | 0.00 | 0.00 |
| Cash Used for Financing Activities | ||||
| Issuance of Capital Stock | 55.86M | 34.78M | 7.18M | 15.97M |
| Repayment of Long-Term Debt | 0.00 | 0.00 | 0.00 | 0.00 |
| Repurchase of Capital Stock | 0.00 | 0.00 | 0.00 | 0.00 |
| Payment of Cash Dividends | 0.00 | 0.00 | 0.00 | 0.00 |
| Other Financing Charges, Net | -3.77M | -2.15M | -468.13K | -260.00K |
| Net Cash From Financing Activities | 52.09M | 32.64M | 6.71M | 15.71M |
| Effect of Exchange Rate Changes | 0.00 | 0.00 | 0.00 | 0.00 |
| Net Change in Cash & Cash Equivalents | -829.00K | 11.54M | -5.45M | 6.94M |
Portfolios with SGYP
- Portfolio NameUser Type
- ContributorBreakout Stocks Of The Week...
- ContributorStocks Under-$10 Moving Hig...
- UserGopher Gold
- ContributorStocks Under-$10 Setting Up...
- ContributorStocks Under-$10 Setting Up...
- ContributorStocks Under-$10 Moving Hig...
- Userpoore mans portfolio
Latest SGYP Headlines from TheStreet
- Synergy Pharmaceuticals Announces Closing Of Public Offering Of Shares Of Common Stock 04.16.13 | 11:04 am
- Synergy Pharmaceuticals Inc. Announces Pricing Of Public Offering Of Common Stock 04.10.13 | 08:04 pm
- Synergy Pharmaceuticals Inc. Announces Public Offering Of Common Stock 04.09.13 | 04:04 pm
- Synergy Pharmaceuticals Reports 2012 Fourth Quarter And Full-Year Financial Results 03.18.13 | 05:03 pm
- Synergy Pharmaceuticals To Present Study Results From Plecanatide Phase IIb/III Trial In Late-Breaking Clinical Abstract At Digestive Disease Week 2013 03.15.13 | 05:03 am
- Synergy Pharmaceuticals To Present At Two Upcoming Investor Conferences 02.22.13 | 06:02 am
- Synergy Pharmaceuticals To Begin Trading On The NASDAQ Global Market 02.11.13 | 05:02 am
- Synergy Pharmaceuticals To Present At Two Upcoming Investor Conferences 02.07.13 | 08:02 am
- Synergy Pharmaceuticals Initiates Multiple Ascending Dose Phase Ib Trial In Healthy Volunteers Of SP-333, A Second Generation Guanylate Cyclase C Agonist For The Treatment Of Ulcerative Colitis 01.28.13 | 05:01 am
- Synergy Pharmaceuticals Announces Approval Of Merger With Callisto Pharmaceuticals And Other Actions At Annual Meeting Of Stockholders 01.15.13 | 05:01 am
Press Releases for SGYP
- Synergy Pharmaceuticals To Present Scientific Posters At The Upcoming Gastroenterology Society Meetings In The U.S. And Europe - PR Newswire 07.31.12 | 12:07 pm
- Synergy Pharmaceuticals To Present At 14th Annual BIO CEO & Investor Conference - Business Wire 02.09.12 | 08:02 am
- Synergy Pharmaceuticals Engages The Trout Group For Investor Relations Services - Business Wire 02.08.12 | 08:02 am
- European Patent Office Upholds Synergy Pharmaceuticals’ Grant Of Claims To Plecanatide - Business Wire 01.04.12 | 06:01 am
- Synergy Pharmaceuticals Announces Full Exercise Of Over-Allotment Option By Aegis Capital Corp. - Business Wire 12.13.11 | 04:12 pm
- Synergy Pharmaceuticals, Inc. Files Suit Against Ironwood Pharmaceuticals, Inc. And Its Chief Scientific Officer And Senior VP Of R&D, Dr. Mark G. Currie - Business Wire 12.13.11 | 03:12 am
- Synergy Pharmaceuticals Inc. Announces Pricing Of Public Offering Of 1,875,000 Units, Listing On NASDAQ And Effectiveness Of Reverse Stock Split - Business Wire 12.01.11 | 08:12 am
- Synergy Pharmaceuticals Raises $5.64 Million In Financing - Business Wire 11.15.11 | 05:11 am
- Synergy Pharmaceuticals And Fox Chase Cancer Center Presentation At 2011 ACG Meeting Highlights Potential Of GC-C Agonists To Delay Progression Of Colitis Into Colon Cancer - Business Wire 10.31.11 | 06:10 am
- Synergy Pharmaceuticals Initiates Dosing Of Patients In Phase II/III Trial Of Plecanatide In Chronic Constipation - Business Wire 10.24.11 | 06:10 am
Partner Headlines for SGYP
- 7 top stocks under $5 - MSN Money 05.16.13 | 03:05 pm
- 5 Healthcare Companies With Recent Insider Buying - Seeking Alpha 11.18.12 | 09:11 am
- IND Submission by Synergy Pharma - Analyst Blog - NASDAQ 09.17.12 | 09:09 pm
- Synergy Acquires FV-100 from BMY - Analyst Blog - NASDAQ 08.28.12 | 10:08 pm
- Synergy Acquires FV-100 from BMY - Analyst Blog - Zacks 08.28.12 | 06:08 pm
- Key Appointment Marks Another Win For Synergy Pharmaceuticals - Seeking Alpha 05.03.12 | 09:05 am
